<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969501</url>
  </required_header>
  <id_info>
    <org_study_id>EUF-SHO-0001</org_study_id>
    <nct_id>NCT00969501</nct_id>
  </id_info>
  <brief_title>Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)</brief_title>
  <official_title>Investigator Initiated, Exploratory Case Study Three Injections of EUFLEXXA (Sodium Hyaluronate)Treatment of Chronic Shoulder Pain Associated With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia Institute for Clinical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgia Institute for Clinical Research, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that by using 3 injections of EUFLEXXA, there will be an
      improvement in pain levels and range of motion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that EUFLEXXA is safe for the treatment of chronic shoulder pain associated
      with osteoarthritis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction in Pain by the Scores.</measure>
    <time_frame>6 months</time_frame>
    <description>Greater than 50 percent reduction in pain scores from baseline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>EUFLEXXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACTIVE CONTROL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUFLEXXA</intervention_name>
    <description>2.5 mL of EUFLEXXA (per injection) x 3 injections</description>
    <arm_group_label>EUFLEXXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be age 30 to 79

          2. Give written informed consent for trial participation

          3. Must have shoulder pain for a minimum of 6 months but less than 5 years

          4. Must have a Pain Intensity Score of &gt; 5

          5. Must be willing to discontinue all pain medications 24 hours prior to each clinic
             visit

          6. Must have a stable pain medication regime 1 month prior to treatment

          7. Agrees to maintain pain medication doses within 30% (increase or decrease) of the
             Baseline dose

        Exclusion Criteria:

          1. Any history of full thickness rotator cuff tear or joint effusion

          2. A diagnosis of chronic acromioclavical disease, active epicondylitis, or active Carpal
             Tunnel Disease

          3. Has had more than 2 corticosteroid injections in the previous 3 months

          4. Has an infection or an inflammatory condition of the trial shoulder

          5. Has acute or inflammatory arthropathy in the trial shoulder, e.g. gouty arthritis,
             psoriatic arthritis or rheumatoid arthritis. Has a history of systemic inflammatory
             arthropathies, e.g. polyarthritis, rheumatoid arthritis, psoriatic arthritis or gout

          6. Has severe joint effusion of the trial shoulder

          7. Has a diagnosis of cancer within the past 5 years (basal cell carcinoma is not
             excluded)

          8. Has had any hyaluronate agent or other chondroprotective agents in the trial shoulder

          9. Has a hypersensitivity to HA products, eggs, birds or feathers

         10. Has a history of substance abuse, alcohol abuse or psychiatric condition, that in the
             opinion of the Investigator, will potentially interfere with participation

         11. Has any medical condition that may increase the risk associated with intra-articular
             injections, to include (but are not limited to): thrombocytopenia, blood disorders
             treated with warfarin or anticoagulants, anemia or other concomitant diseases that, in
             the opinion of the Investigator, will interfere with the evaluation of the trial
             treatment, e.g., renal or liver disease, uncontrolled diabetes, significant
             cardiovascular, immune deficiency, or infectious disease

         12. Is actively involved in a litigation involving Workers' Compensation

         13. Is a female that is pregnant, planning to become pregnant or is lactating

         14. Has participated in a clinical trial within the past four weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold J. Weil, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgia Institute for Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research, LLC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <results_first_submitted>September 5, 2012</results_first_submitted>
  <results_first_submitted_qc>March 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2013</results_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgia Institute for Clinical Research, LLC</investigator_affiliation>
    <investigator_full_name>Arnold J. Weil, M.D.</investigator_full_name>
    <investigator_title>M.D./CEO/Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EUFLEXXA</title>
          <description>All subjects received three injections (one each, in weeks 0 [baseline], 1, and 2 of high molecular weight hyaluronate (2.5 mL each) using standard injection techniques in the anterior or posterior approach. Sub- jects were evaluated at screening and baseline, and at weeks 1, 2, 6, 14, 26, and 27 (last evaluation by telephone).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EUFLEXXA</title>
          <description>ACTIVE CONTROL</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction in Pain by the Scores.</title>
        <description>Greater than 50 percent reduction in pain scores from baseline.</description>
        <time_frame>6 months</time_frame>
        <population>￼</population>
        <group_list>
          <group group_id="O1">
            <title>EUFLEXXA</title>
            <description>ACTIVE CONTROL</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction in Pain by the Scores.</title>
          <description>Greater than 50 percent reduction in pain scores from baseline.</description>
          <population>￼</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EUFLEXXA</title>
          <description>ACTIVE CONTROL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arnold Weil, MD</name_or_title>
      <organization>Georgia Institute for Clinical Research, LLC</organization>
      <phone>770-421-2030</phone>
      <email>research@lowbackpain.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

